Drug Profile
Research programme: chimeric antigen receptor T cell therapy - Celularity/Sorrento Therapeutics/TNK Therapeutics
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics; TNK Therapeutics
- Developer Celularity
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA
- 28 Mar 2023 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in Non-Hodgkin's lymphoma and Precursor cell lymphoblastic leukaemia-lymphoma presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)